An increase in the probability of success suggests positive clinical data or regulatory progress, enhancing the asset's expected value. A decrease signals potential development hurdles, clinical failures, or regulatory setbacks.
The estimated likelihood that the HLD-0915 product candidate will successfully navigate clinical trials, regulatory appr...
Standard industry practice for valuing biotech and pharmaceutical pipelines, often benchmarked against historical success rates for similar therapeutic classes.
jnj_segment_hld_0915_probability_of_success_factor| Q4 '25 | |
|---|---|
| Value | $0.68 |